Anti-BCMA novel therapies for multiple myeloma

Vincenzo Sammartano; Marta Franceschini; Sara Fredducci; Federico Caroni; Sara Ciofini; Paola Pacelli; Monica Bocchia; Alessandro Gozzetti

doi:10.20517/cdr.2022.138

Anti-BCMA novel therapies for multiple myeloma

Cancer Drug Resist. 2023 Mar 22;6(1):169-181. doi: 10.20517/cdr.2022.138. eCollection 2023.

Authors

Vincenzo Sammartano^{1

2}, Marta Franceschini^{1

2}, Sara Fredducci^{1

2}, Federico Caroni^{1

2}, Sara Ciofini^{1

2}, Paola Pacelli^{1

2}, Monica Bocchia², Alessandro Gozzetti²

Affiliations

¹ Department of Medicine, Surgery and Neuroscience, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena 53100, Italy.
² Authors share last co-authorship.

Abstract

Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.

Keywords: BCMA; CART; Multiple myeloma; belantamab; teclistamab.

Publication types

Review